Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fphar.2017.00564 http://scihub22266oqcxt.onion/10.3389/fphar.2017.00564 C5583590!5583590 !28912715     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28912715 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28912715 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Front+Pharmacol 2017 ; 8 (ä): 564 Nephropedia Template TP {{tp|p=28912715 |t=2017. Anti-fibrotic Potential of AT(2) Receptor Agonists |pdf=|usr=}}{{28912715 }} gab.com Text Anti-fibrotic Potential of AT(2) Receptor Agonists JO: Front Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=28912715 #FOAvip There are a number of therapeutic targets to treat organ fibrosis that are under investigation in preclinical models. There is increasing evidence that stimulation of the angiotensin II type 2 receptor (AT(2)R) is a novel anti-fibrotic strategy and we have reviewed the published in vivo preclinical data relating to the effects of compound 21 (C21), which is the only nonpeptide AT(2)R agonist that is currently available for use in chronic preclinical studies. In particular, the differential influence of AT(2)R on extracellular matrix status in various preclinical fibrotic models is discussed. Collectively, these studies demonstrate that pharmacological AT(2)R stimulation using C21 decreases organ fibrosis, which has been most studied in the setting of cardiovascular and renal disease. In addition, AT(2)R-mediated anti-inflammatory effects may contribute to the beneficial AT(2)R-mediated anti-fibrotic effects seen in preclinical models. Twit Text FOAVip Anti-fibrotic Potential of AT(2) Receptor Agonists ????Front Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=28912715 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28912715 #FOAvip English Wikipedia <ref>{{Cite pmid|28912715 }}</ref> Anti-fibrotic Potential of AT(2) Receptor Agonists #MMPMID28912715 Wang Y ; Del Borgo M ; Lee HW ; Baraldi D ; Hirmiz B ; Gaspari TA ; Denton KM ; Aguilar MI ; Samuel CS ; Widdop RE Front Pharmacol 2017[]; 8 (ä): 564 PMID28912715 show ga There are a number of therapeutic targets to treat organ fibrosis that are under investigation in preclinical models. There is increasing evidence that stimulation of the angiotensin II type 2 receptor (AT(2)R) is a novel anti-fibrotic strategy and we have reviewed the published in vivo preclinical data relating to the effects of compound 21 (C21), which is the only nonpeptide AT(2)R agonist that is currently available for use in chronic preclinical studies. In particular, the differential influence of AT(2)R on extracellular matrix status in various preclinical fibrotic models is discussed. Collectively, these studies demonstrate that pharmacological AT(2)R stimulation using C21 decreases organ fibrosis, which has been most studied in the setting of cardiovascular and renal disease. In addition, AT(2)R-mediated anti-inflammatory effects may contribute to the beneficial AT(2)R-mediated anti-fibrotic effects seen in preclinical models. äAnti-fibrotic Potential of AT(2) Receptor Agonists (epmc).pdf DeepDyve Pubget Overpricing